• Bulevirtide in the Treatment of Hepatitis Delta: Drug Discovery, Clinical Development and Place in Therapy 

      Soriano, Vicente; Moreno-Torres, Víctor; Treviño, Ana; Corral, Octavio Jorge; de Mendoza, Carmen (Drug Design, Development and Therapy, 2023)
      It has been ten years since the identification of NTCP as the cell surface receptor for HBV and HDV entry into hepatocytes. The search for molecules interfering with the binding of NTCP and HBV/HDV led to design bulevirtide ...
    • Envisioning a hepatitis delta cure with new antivirals 

      Soriano, Vicente ; Mendoza, Carmen de; Barreiro, Pablo; Treviño, Ana ; Corral, Octavio Jorge (Future Medicine Ltd., 2021)
      Envisioning a hepatitis delta cure with new antivirals
    • Impact of potent nucleos(t)ide therapy on hepatitis B hospitalisations in Spain 

      Ramos-Rincón, José-Manuel; Pinargote-Celorio, Héctor; de Mendoza, Carmen; Ramos-Belinchón, Clara; Barreiro, Pablo; Treviño, Ana; Corral, Octavio Jorge; Soriano, Vicente (Alimentary Pharmacology and Therapeutics, 2023)
      Background: Chronic hepatitis B virus (HBV) infection is a major cause of decompensated cirrhosis and liver cancer worldwide. Newborn HBV vaccination was implemented in Spain two decades ago, and potent oral antivirals ...
    • Occult hepatitis B and HIV infection 

      Soriano, Vicente ; Aguilera, Antonio; González, Rocío; Gómez-Gallego, Felix ; Barea, Luisa; Treviño, Mercedes; Corral, Octavio Jorge (European Journal of Gastroenterology & Hepatology, 11/2019)
      Introduction Occult hepatitis B virus (HBV) infection, so-called occult B infection (OBI), is defined by the recognition of HBV-DNA in the absence of serum hepatitis B surface antigen (HBsAg). The HBV-DNA genome in OBI is ...